Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues        
Royalty $ 0 $ 1,872 $ 0 $ 2,112
Product 24,782 3,322 50,312 3,626
Total Revenues 24,782 5,194 50,312 5,738
Operating Expenses        
Research and development 3,649,469 3,492,845 7,522,547 7,387,811
General and administrative 1,816,599 1,508,836 3,626,759 3,212,358
Sales and marketing 459,371 215,891 886,772 489,845
Total Operating Expenses 5,925,439 5,217,572 12,036,078 11,090,014
Operating Loss (5,900,657) (5,212,378) (11,985,766) (11,084,276)
Other Income (Expenses)        
Grant income 391,532 90,946 391,532 98,870
(Loss) / Gain on disposal of fixed assets (26,166) 93,202 (26,167) 93,202
Interest income 492 7,741 2,213 46,155
Interest expense (39,688) (22,604) (81,869) (56,383)
Total Other Income (Expenses) 326,170 169,285 285,709 181,844
Net Loss (5,574,487) (5,043,093) (11,700,057) (10,902,432)
Net Loss attributable to Non-Controlling Interest 47,539 5,779 56,963 15,346
Net Loss attributable to VolitionRx Limited Stockholders (5,526,948) (5,037,314) (11,643,094) (10,887,086)
Other Comprehensive Income (Loss)        
Foreign currency translation adjustments (44,548) (74,320) 89,585 299,606
Net Comprehensive Loss $ (5,619,035) $ (5,117,413) $ (11,610,472) $ (10,602,826)
Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited $ (0.10) $ (0.12) $ (0.22) $ (0.26)
Weighted Average Shares Outstanding        
- Basic and Diluted 52,947,173 43,414,318 51,943,534 42,312,172